Literature DB >> 22193855

Spondyloarthropathies: the disease process in axial SpA: what can biomarkers tell us?

Jürgen Braun, Xenofon Baraliakos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22193855     DOI： 10.1038/nrrheum.2011.187

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.

Authors:  Marissa N Lassere; Kent R Johnson; Maarten Boers; Peter Tugwell; Peter Brooks; Lee Simon; Vibeke Strand; Philip G Conaghan; Mikkel Ostergaard; Walter P Maksymowych; Robert Landewe; Barry Bresnihan; Paul-Peter Tak; Richard Wakefield; Philip Mease; Clifton O Bingham; Michael Hughes; Doug Altman; Marc Buyse; Sally Galbraith; George Wells
Journal:  J Rheumatol       Date:  2007-03       Impact factor: 4.666

2.  Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis.

Authors:  Praveena Chiowchanwisawakit; Robert G W Lambert; Barbara Conner-Spady; Walter P Maksymowych
Journal:  Arthritis Rheum       Date:  2011-08

3.  Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover.

Authors:  Susanne Juhl Pedersen; Inge Juul Sørensen; Robert G W Lambert; Kay-Geert A Hermann; Patrick Garnero; Julia Sidenius Johansen; Ole Rintek Madsen; Annette Hansen; Michael Sejer Hansen; Gorm Thamsborg; Lis Smedegaard Andersen; Ole Majgaard; Anne Gitte Loft; Jon Erlendsson; Karsten H Asmussen; Anne Grethe Jurik; Jakob Møller; Maria Hasselquist; Dorrit Mikkelsen; Mikkel Østergaard
Journal:  Arthritis Rheum       Date:  2011-12

4.  ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.

Authors:  Susanne Juhl Pedersen; Inge Juul Sørensen; Patrick Garnero; Julia Sidenius Johansen; Ole Rintek Madsen; Niels Tvede; Michael Sejer Hansen; Gorm Thamsborg; Lis Smedegaard Andersen; Ole Majgaard; Anne Gitte Loft; Jon Erlendsson; Karsten Asmussen; Anne Grethe Jurik; Jakob Møller; Maria Hasselquist; Dorrit Mikkelsen; Thomas Skjødt; Robert Lambert; Annette Hansen; Mikkel Østergaard
Journal:  Ann Rheum Dis       Date:  2011-05-08       Impact factor: 19.103

Review 5.  Imaging of axial spondyloarthritis including ankylosing spondylitis.

Authors:  J Braun; X Baraliakos
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

6.  Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis.

Authors:  Heiner Appel; Gisela Ruiz-Heiland; Joachim Listing; Jochen Zwerina; Martin Herrmann; Ruediger Mueller; Hildrun Haibel; Xenofon Baraliakos; Axel Hempfing; Martin Rudwaleit; Joachim Sieper; Georg Schett
Journal:  Arthritis Rheum       Date:  2009-11

7.  Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis.

Authors:  Walter P Maksymowych; Robert Landewé; Barbara Conner-Spady; Maxime Dougados; Herman Mielants; Hille van der Tempel; A Robin Poole; Nandi Wang; Désirée van der Heijde
Journal:  Arthritis Rheum       Date:  2007-06

8.  Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.

Authors:  S Visvanathan; C Wagner; J C Marini; D Baker; T Gathany; J Han; D van der Heijde; J Braun
Journal:  Ann Rheum Dis       Date:  2007-07-20       Impact factor: 19.103

9.  The relationship between inflammation and new bone formation in patients with ankylosing spondylitis.

Authors:  Xenofon Baraliakos; Joachim Listing; Martin Rudwaleit; Joachim Sieper; Juergen Braun
Journal:  Arthritis Res Ther       Date:  2008-09-01       Impact factor: 5.156

10.  Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis.

Authors:  S Visvanathan; D van der Heijde; A Deodhar; C Wagner; D G Baker; J Han; J Braun
Journal:  Ann Rheum Dis       Date:  2008-05-21       Impact factor: 19.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.